Santhera Pharmaceuticals Holding AG (SPHDF)
19.79
0.00 (0.00%)
USD |
OTCM |
Sep 24, 16:00
Santhera Pharmaceuticals Research and Development Expense (Annual) : 26.75M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 26.75M |
| December 31, 2024 | 30.05M |
| December 31, 2023 | 20.78M |
| December 31, 2022 | 31.97M |
| December 31, 2021 | 32.50M |
| December 31, 2020 | 36.47M |
| December 31, 2019 | 41.50M |
| December 31, 2018 | 39.07M |
| December 31, 2017 | 26.99M |
| December 31, 2016 | 17.94M |
| December 31, 2015 | 10.86M |
| December 31, 2014 | 6.419M |
| Date | Value |
|---|---|
| December 31, 2013 | 4.492M |
| December 31, 2012 | 9.413M |
| December 31, 2011 | 20.44M |
| December 31, 2010 | 15.05M |
| December 31, 2009 | 29.05M |
| December 31, 2008 | 29.06M |
| December 31, 2007 | 19.45M |
| December 31, 2006 | 14.35M |
| December 31, 2005 | 18.06M |
| December 31, 2004 | 11.16M |
| December 31, 2003 | 7.817M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Basilea Pharmaceutica AG | 127.51M |
| BeOne Medicines Ltd. | 2.079B |
| AC Immune SA | 67.96M |
| CRISPR Therapeutics AG | 265.33M |
| Idorsia Ltd. | 121.54M |